<DOC>
	<DOCNO>NCT00675987</DOCNO>
	<brief_summary>The main purpose study find study drug losartan ( Cozaar ) placebo ( `` sugar pill '' ) effect insulin sensitivity ( body respond insulin ) measure effect study drug losartan placebo artery arm dilate ( enlarge carry blood ) . We hope learn take losartan change amount certain protein blood effect blood vessel function . Losartan approve US FDA treat high blood pressure . It take approximately 4 month complete study .</brief_summary>
	<brief_title>A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction Insulin Resistance In Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Currently take 1 antihypertensive medication Male female 18 75 year age Mean trough sit diastolic blood pressure ( SiDBP ) ≥80 &lt; 100 mm Hg Mean trough sit systolic blood pressure ( SiSBP ) ≥120 &lt; 160 mm Hg Nondiabetic patient fast plasma glucose ≥100 mg/dL &lt; 126 mg/dL Body mass index ( BMI ) &gt; 30 &lt; 40 Waist circumference &gt; 40 inch male , &gt; 35 inch females A patient reproductive potential agrees remain abstinent use acceptable method birth control ( intrauterine device ( IUD ) , diaphragm spermicide , contraceptive sponge , condom , hormonal contraception , vasectomy ) within project duration study Secondary hypertension etiology ( renal artery stenosis , coarctation aorta pheochromocytoma , hypertension induce oral contraceptive ) History malignant hypertension Any clinically significant renal disease include single functioning kidney , know history anuria . Any severe renal impairment , manifest serum creatinine 1.5 mg/dL , proteinuria &gt; 2+ urine dipstick Known sensitivity intolerance angiotensin II receptor antagonist Type I II diabetes Inability unwillingness abstain take prohibited medication study period History myocardial infarction ( MI ) , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) , congestive heart failure ( CHF ) , unstable angina , transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) Concomitant cardiac condition would make unsafe participate trial ( e.g. , clinically significant atrioventricular ( AV ) conduction disturbance , atrial flutter , atrial fibrillation , potentially lifethreatening ventricular arrhythmia , decompensated valvular disease , presence hemodynamically significant obstructive valvular disease , cardiomyopathy ) History angioedema and/or organ damage hypertension Serum potassium &lt; 3.5 &gt; 5.5 mEq/L Any clinically significant laboratory value investigator 's judgment could clinically significant outcome study . History clinically important gastrointestinal resection malabsorption Patient history current evident condition , therapy , lab abnormality , circumstance might confound result study , interfere patient 's participation full duration study , best interest patient participate . ( Including limit : recent current alcoholism , drug abuse within prior 2 year , mental legal incapacitation , disease could reasonably expect fatal lifethreatening , history malignancy ≤ 5 year prior sign inform consent . ) Currently participate participate study investigational compound device within 30 day sign informed consent . Inability take current antihypertensive medication place placebo 12 week . Unwillingness unlikely adhere study procedure , keep appointment , plan relocate study . Arm circumference great 52 cm Smokers former smoker quite less 1 year prior Visit 1 Anemia ( Hemoglobin &lt; 11 ) Allergy latex Deformed hand and/or finger would interfere collection pulse volume amplitude measurement History Raynaud 's disease vascular condition Bilateral mastectomy Aortic stenosis Patient take high dos antioxidant supplement ( vitamin , mineral , )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Impaired Fasting Glucose FPG &gt; 100- &lt; 126 mg/dL</keyword>
</DOC>